Journal Article

DZNE-2025-00223

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer's disease: a case series.

Wagemann, O. (First author)DZNE* ; Brendel, M.Extern* ; Franzmeier, N. ; Nübling, G.DZNE* ; Gnoerich, J.Extern* ; Zaganjori, M. ; Prix, C.Extern* ; Stockbauer, A.DZNE* ; Wlasich, E. ; Loosli, S. V. ; Sandkühler, K. ; Frontzkowski, L. ; Höglinger, G.DZNE* ; Levin, J. (Last author)DZNE*

2025
Frontiers Research Foundation Lausanne

This record in other databases:    

Please use a persistent id in citations: doi:10.3389/fnins.2024.1505999

Abstract: Adults with Down Syndrome (DS) have a substantially increased risk for Alzheimer's disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-AD research or clinical work-up, and second-generation tau tracers such as [18F]PI-2620 have not been thoroughly characterized in adults with DS. We aim at illustrating feasibility and potential diagnostic value of tau PET imaging with [18F]PI-2620 for the diagnosis of DS-AD.Five adults with DS (40% female, aged 43-62) and cognitive decline underwent clinical assessments, neuropsychological testing, lumbar puncture and multimodal neuroimaging. All underwent [18F]PI-2620 tau PET. Visual read of tau PET scans was performed by three blinded raters, assessing increased tracer uptake in brain areas corresponding to the six Braak stage regions and basal ganglia.Visual read of tau burden revealed three tau-positive individuals which corresponded to their clinical decline while two cognitively stable individuals were rated as negative. Rating showed high inter-rater reliability for all Braak stages.Tau PET imaging is a feasible and important biomarker assessment in the differential diagnosis of cognitive decline in adults with DS at risk of developing AD.

Keyword(s): 18F-PI-2620 ; Alzheimer ; case series ; down syndrome ; tau PET ; trisomy 21

---

Contributing Institute(s):

1. Clinical Research (Munich) (Clinical Research (Munich))
2. Clinical Neurodegeneration (AG Levin)
3. Molecular Neurobiology (AG Simons)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
2. 351 - Brain Function (POF4-351) (POF4-351)

Appears in the scientific report 2025

---

Database coverage:
; ; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---